MarketPulse

Huntington's Disease

12 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Securities Class Action Filed Against uniQure Over FDA Approval Misrepresentations

Securities class action filed against uniQure alleging FDA approval misrepresentations. April 13, 2026 deadline for lead plaintiff claims.
QUREsecurities class actionFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

uniQure Faces Securities Fraud Lawsuit Over Huntington's Gene Therapy Misstatements

Kessler Topaz files class action against $QURE over alleged misleading statements about AMT-130 FDA approval timeline, following 49% stock plunge in November 2025.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

uniQure Hit With Securities Fraud Suit Over Gene Therapy Misstatements

Class action lawsuit filed against $QURE over alleged misstatements about Huntington's disease therapy approval timeline. Stock crashed 49% after FDA stance shift.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

uniQure Faces Securities Lawsuit Over Huntington's Study Design Misrepresentation

uniQure faces securities lawsuit for allegedly misrepresenting Huntington's study design approval and downplaying BLA delays. Investors must act by April 13, 2026.
QUREsecurities class actionFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

uniQure Stock Crashes 49% as Gene Therapy Lawsuit Alleges FDA Misrepresentations

Class action lawsuit filed against $QURE over alleged misstatements about AMT-130 gene therapy FDA approval status. Stock plunged 49% after FDA reversed position on Phase I/II data adequacy.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

uniQure Stock Crashes 49% as FDA Rejects Huntington's Gene Therapy Pathway

uniQure's $QURE stock crashes 49% after FDA rejects Huntington's gene therapy approval pathway; securities fraud lawsuit filed alleging misleading statements about regulatory expectations.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

uniQure Faces Securities Lawsuit Over FDA Study Design Misrepresentations

uniQure faces securities class action over alleged misrepresentations regarding FDA approval status of Huntington's Disease trial design and regulatory timeline delays. Lead plaintiff deadline April 13, 2026.
QUREsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

UniQure Investors Urged to Consult Legal Counsel Ahead of Securities Suit Deadline

UniQure faces securities lawsuit alleging material misrepresentations about its Huntington's Disease trial design and FDA approval status. Lead plaintiff deadline is April 13, 2026.
QUREsecurities class actionFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Class Action Deadline Looms for uniQure Investors Amid FDA Approval Claims

uniQure faces securities class action over allegedly misleading FDA approval claims and timeline delays. Investors must act before April 13, 2026 deadline.
QUREVTGNLUinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

uniQure Investors Face April Deadline in Securities Litigation Over FDA Disclosure Claims

UniQure faces class action lawsuit over alleged FDA disclosure misrepresentations. Investors have until April 13, 2026 deadline to join litigation.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

Securities Litigation Filed Against uniQure Over Gene Therapy Trial Misstatements

Law firm sues uniQure for allegedly misrepresenting gene therapy trial status and FDA approval timeline, causing stock to surge 250% then fall 49% after FDA reversal.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Class Action Lawsuit Filed Against uniQure Over FDA Approval Disclosures

Rosen Law Firm sued uniQure for allegedly misleading investors about FDA approval timelines and regulatory study status between September-October 2025.
QUREsecurities fraudclass action lawsuit